WO2000071145A1 - Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales - Google Patents

Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales Download PDF

Info

Publication number
WO2000071145A1
WO2000071145A1 PCT/KR1999/000316 KR9900316W WO0071145A1 WO 2000071145 A1 WO2000071145 A1 WO 2000071145A1 KR 9900316 W KR9900316 W KR 9900316W WO 0071145 A1 WO0071145 A1 WO 0071145A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
taurine
hangover
ginkgo biloba
Prior art date
Application number
PCT/KR1999/000316
Other languages
English (en)
Inventor
Hee Jung Kim
Yeong Chul Park
Original Assignee
Hee Jung Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hee Jung Kim filed Critical Hee Jung Kim
Priority to AU43982/99A priority Critical patent/AU4398299A/en
Publication of WO2000071145A1 publication Critical patent/WO2000071145A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom

Definitions

  • the present invention relates generally to the recovery from drunken conditions and to the prevention of brain cell damage, and especially to novel compositions used to recover from a hangover by alcohol and to prevent brain cell damage, and to a process to produce the composition therein.
  • a hangover is a physical pain of the human body after one has drunk alcohol m excess.
  • a hangover involves the mam symptoms such as a headacne with vomiting, a stomachache and a brash of sour stomach, etc.
  • Intestinal brash and the like which are caused by excessive secretion of gastric juices, that is, gastric hyperacidity due to ethanol itself, can be improved and restored by internal use of antacid.
  • a headache due to a hangover is generally known to result from acetaldehyde as the metabolite of alcohol.
  • Acetaldehyde affects nerve cells in the cerebrum and the cerebellum and so on, and recently, is known to be accumulated m a large amount withm the cerebellum. Additionally, the anesthetic effect of ethyl alcohol is so strong that it makes one feel no headache, even though acetaldehyde is produced while drinking wine. However, it has been found that the headache caused by acetaldehyde does not occur until the ethanol level m blood is lowered, followed by a decrease in anesthetic effect. Acetaldehyde, in particular, causes the contraction of cerebral blood vessels and allows the blood flow rate to decrease so that it consequently causes severe pain.
  • cerebral cells generate ATPs (abbr. of "adenos e triphosphate” ) only from saccharides, compared to the cells in other areas of tne body that use carbohydrates, fats and saccharides to produce ATPs as an energy source.
  • Ethanol reduces the level of blood sugar so that the pain grows worse by the deficiency of energy.
  • Oxidative stress caused by ethanol and acetaldehyde has been disclosed to occur if antioxidant materials cells which are required to eliminate free radicals generated during the energy metabolism are decreased.
  • free radicals increase during the process of the metabolism of ethanol and derive oxidation of the glutathion (GSH) which shows the strongest antioxidation effect among different antioxidation enzymes and/or substances m cells.
  • the human body is exposed to various toxic materials contained m contaminated environments and can metabolize them to produce narmful free radicals.
  • the free radicals can induce brain cells damage and cause serious brain disease such as Alzheimer's disease.
  • Ginkgo biloba extract has been used to treat asthma or bronchitis as a Chinese medicine m China for a long time, and recently, it has been known that the extract of ginkgo leaves is on the market m the areas of Europe and Asia as a medical agent to treat senile peripheral neuropathy (or peripheral nerve disorder) , cerebrovascular disorder and/or asthma.
  • Taurine is an important suostance m the human body. Octopuses, squids, shrimps and clams are known to contain large amounts of taurine. It has been known that taurine can protect the liver, help one recover from fatigue, protect one's eyesight, and prevent and treat stomach ulcers and duodenum ulcers.
  • the present inventor studied the method to remove acetaldehydes inducing the headaches, thereby finding that the contents of the acetaldehydes m blood can be effectively reduced by combining acetaldehydes with taurine to form complexes, further, using the blood circulation effect of "Gmgko" and thus accomplishing the present invention.
  • the inventor has achieved the protection of cerebral oxidative damage caused by ethanol and acetaldehyde.
  • composition according to the present invention has a significant effect preventing brain cell damage due to exposure to various harmful materials .
  • the primary ob ect of the present invention is to provide new compositions to restore and recover the body from drunken conditions due to alcohol.
  • Another object of the present invention is to provide new pharmaceutical compositions to prevent bram cell damage.
  • the present invention relates to a medicine or a composition comprising "Ginkgo biloba extract” and “Taurine” for recovering from a hangover.
  • composition above may contain sugar, Ostrea gigas and Amomum villosum.
  • Fig. 1 is a graphic representation of the effect of taurine (“Tau”) m reducing acetaldehyde (“AcH”) m blood.
  • Fig. 2 is a graphic representation of the relation between the amount and the reaction of AcH and Tau.
  • Fig. 3 shows the analysis result of the structure of the AcH + Tau complex by GC mass.
  • Fig. 4 is a graphic representation of the effects of Ginkgo biloba extract ( "Gbe” ) and Tau to the peroxidation of ethanol-denved lipids.
  • Fig. 5 is a graphic representation of the effects of Gbe and Tau to the carbonylation of ethanol-denved protein.
  • Fig. 6 is a graphic representation of the effects of Gbe + Tau on headaches induced by wme.
  • compositions of the present invention for recovering from a hangover and for preventing bram cell damage comprise Ginkgo biloba extract and taurine.
  • Ginkgo biloba extract contained in the composition can improve the antioxidative effect resistant to tne damage by ethanol-denved oxidation and facilitate the cerebrovascular circulation to remove acetaldehyde as the metabolite of ethanol in the cerebral blood vessels.
  • Taurine contained m the present composition generates a complex withm the acetaldehyde excluded from the bram and blood vessels so that it prevents the acetaldehyde along with hemokmesis to flow back into the bram.
  • the composition according to the present invention may preferably include 0.01-10.0wt% Ginkgo biloba extract and 0.01-10.0wt% taurine per 100 ml of the composition.
  • Ginkgo biloba extract is on the market or is directly obtained from ginkgo leaves by the processes of extracting the leaves and filtering and drying the supernatant .
  • the present composition can be prepared by adding Ginkgo biloba extract and Taurine into edible water, admixing them at room temperature and further adding known and acceptable additives such as preservatives and flavorings m sufficient amounts to produce the desired effect.
  • composition may optionally and/or totally contain sugar, Ostrea gigas extract or Amomum villosum extract.
  • Ostrea gigas extract which functions as an antacid to protect against intestinal brash owing to acid indigestion can be obtained by heating oyster shells.
  • Ostrea gigas extract may be on a market or directly obtained from oyster shells by the processes of extracting, filtering and drying Known m the art .
  • Amomum villosum extract from a ginger geneic nut which functions as a constipant to prevent diarrhea and effects to remove intestinal gas may be on a market or directly obtained by the known methods of extracting, filtering and drying it.
  • composition of the present invention optionally includes at least one or more of the following ingredients: 0.1-30 wt.% sugar, 0.01-10 wt.% Ostrea gigas extract and/or 0.01-10 wt.?: Amomum villosum extract per 100ml of the composition, together with Ginkgo biloba extract and Taurine.
  • the pharmaceutical composition according to the present invention may be manufactured by 0.01-10.0 wt% Ginkgo biloba extract and 0.01-10 wt% taurine per each tablet together with other conventional additives such as diluent, binder, etc. by conventional pharmaceutical preparation.
  • the pharmaceutical composition according to the present invention may be manufactured to be in a granular form preparation.
  • compositions according to the present invention significantly reduce the concentration of aldehyde in blood compared to that of alcohol-treated group and prevent oxidative damage of bram cells.
  • compositions according to the present invention protect bram cells from oxidative damage as well as help m the recovery from a hangover.
  • a drinkable beverage composition is prepared by mixing the following ingredients m 1 liter of edible water :
  • Example 2 A drinkable beverage composition is prepared by mixing the following ingredients m 1 liter of edible water:
  • a driniable beverage composition is prepared by mixing the following ingredients m 1 liter of edible water:
  • Citric acid 0. lg
  • Example 4 Tablets according to the composition of the invention are prepared by conventional pharmaceutical preparation methods with the following ingredients:
  • Example 5 The reduction of acetaldehyde concentration in blood by taurine
  • Oxidation damage of bram tissue was measured in rats 8 hours after oral administration of 2 ml of 25% ethanol at intervals of 30 minutes. 1 hour before sacrificing the animals, a 15mg/kg body weight dosage of taurine and 1.5mg/kg body weight of Ginkgo biloba extract was administered. Also, damage of brain tissue by oxidative stress was measured in a control group by sacrificing rats 30 minutes after oral administration of 2 ml of 10% acetaldehyde. Each group comprised 4 to 6 rats and the brain tissue of the sacrificed rats was preserved in liquid nitrogen. Within 3 days after sacrificing the rats, lg of brain tissue was sampled and homogenized in 3 m of 1.15% KCl buffer. Homogenized samples were centrifuged for 10 min.
  • Fig. 1 shows that acetaldehyde concentration in the blood for the taurine-treated group is 0.0013% whereas that for the acetaldehyde-control group is 0.012%. Therefore, acetaldehyde concentration in the blood was lowered ten times by administering taurine.
  • Fig. 4 and Fig. 5 show the results of the above experiment.
  • oxidative damage amount of TBARS ( thiobarbituric acid-reacting substance) and amount of protein carbonyl group
  • m the bram tissue of the rats sacrificed 6 hours after administering ethanol increased 25-30% in comparison to the normal control group.
  • the damage was significantly decreased in the Ginkgo biloba extracts- treated and/or the taurme-treated group.
  • Example 7 The effect on headaches induced by ethanol
  • composition according to said Example 1, was administered to 40 men and women, m age ranging from their twenties to their fifties, suffering headaches the next morning after drmkmg and the result is shown in Fig. 6.
  • the composition was administered on an empty stomach the next morning after drmkmg. 33 out of 40 persons (83%) recovered from their headaches.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à une nouvelle composition permettant de soulager les symptômes liés à la 'gueule de bois' et provoqués par un abus d'alcool, et d'éviter la destruction de cellules cérébrales. L'invention se rapporte également à la préparation d'une telle composition qui contient de l'extrait de Ginkgo biloba et de la taurine, en quantités représentant respectivement, de préférence, 0,01 à 10,0 % en poids et 0,01 à 10,0 % en poids pour 1 ml de composition. Elle peut en outre contenir éventuellement au moins un des composés tels que du sucre, de l'extrait d'Ostrea gigas et/ou de l'extrait d'Amomum villosum. Cette composition peut se présenter sous forme de boisson, de comprimés ou de granulés et être obtenue selon des procédés de préparation pharmaceutiques classiques.
PCT/KR1999/000316 1999-05-24 1999-06-19 Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales WO2000071145A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43982/99A AU4398299A (en) 1999-05-24 1999-06-19 Composition for recovering from a hangover and for preventing brain cell damage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759099A 1999-05-24 1999-05-24
US09/317,590 1999-05-24

Publications (1)

Publication Number Publication Date
WO2000071145A1 true WO2000071145A1 (fr) 2000-11-30

Family

ID=23234377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1999/000316 WO2000071145A1 (fr) 1999-05-24 1999-06-19 Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales

Country Status (2)

Country Link
AU (1) AU4398299A (fr)
WO (1) WO2000071145A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913769B2 (en) 2003-02-18 2005-07-05 Brian Douglas Oslick Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption
WO2006103316A1 (fr) * 2005-04-01 2006-10-05 Biohit Oyj Préparation alimentaire se liant à l'acétaldéhyde présent dans la bouche et dans l'appareil digestif, et méthode d'élaboration de ladite préparation
EP1997500A1 (fr) * 2007-05-29 2008-12-03 Young-Sam Jang Thé bon pour la santé et son procédé de préparation
US9474733B2 (en) 2000-10-30 2016-10-25 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
US11096904B2 (en) * 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004165A1 (fr) * 1987-10-19 1989-05-18 Haklitch Joseph A Complement alimentaire de desintoxication
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
CN1113765A (zh) * 1994-06-23 1995-12-27 深圳海王药业有限公司 护肝解酒制剂的配制方法
JPH1094382A (ja) * 1996-09-20 1998-04-14 Otsuka Yakuhin Kogyo Kk ステビア濃縮液配合による健脳食の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004165A1 (fr) * 1987-10-19 1989-05-18 Haklitch Joseph A Complement alimentaire de desintoxication
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
CN1113765A (zh) * 1994-06-23 1995-12-27 深圳海王药业有限公司 护肝解酒制剂的配制方法
JPH1094382A (ja) * 1996-09-20 1998-04-14 Otsuka Yakuhin Kogyo Kk ステビア濃縮液配合による健脳食の製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 1997-416159 *
PATENT ABSTRACTS OF JAPAN vol. 199, no. 809 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474733B2 (en) 2000-10-30 2016-10-25 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
US6913769B2 (en) 2003-02-18 2005-07-05 Brian Douglas Oslick Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption
US6967031B1 (en) 2003-02-18 2005-11-22 Brian Douglas Oslick Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption
WO2006103316A1 (fr) * 2005-04-01 2006-10-05 Biohit Oyj Préparation alimentaire se liant à l'acétaldéhyde présent dans la bouche et dans l'appareil digestif, et méthode d'élaboration de ladite préparation
US8227513B2 (en) 2005-04-01 2012-07-24 Biohit Oyj Food composition for binding acetaldehyde in mouth and in digestive track, and method for the preparation of the composition
EA017831B1 (ru) * 2005-04-01 2013-03-29 Биохит Оий Пищевая композиция, связывающая ацетальдегид, и способ её приготовления
CN104172194A (zh) * 2005-04-01 2014-12-03 拜奥希特公司 用以结合口腔和消化道中的乙醛的食物组合物和制备该组合物的方法
EP1997500A1 (fr) * 2007-05-29 2008-12-03 Young-Sam Jang Thé bon pour la santé et son procédé de préparation
JP2008295452A (ja) * 2007-05-29 2008-12-11 Young-Sam Jang 自然健康茶及びその製造方法
US11096904B2 (en) * 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia
US11571395B2 (en) 2018-05-11 2023-02-07 Kaplan Ip, Llc Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia

Also Published As

Publication number Publication date
AU4398299A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
CA2234954A1 (fr) Composition a complement vitaminique multiple
JP2008273938A (ja) アディポネクチン産生促進剤
US20150374745A1 (en) Nutrients solutions for enhancement of cognitive function
JP5694628B2 (ja) 肝機能改善剤
US5482712A (en) Galenic composition
US20180028473A1 (en) Nutrients solutions
JP2006193502A (ja) アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬
JP2009298769A (ja) 脂肪蓄積抑制用組成物
WO2000071145A1 (fr) Composition permettant de soulager les symptomes lies a la 'gueule de bois' et d'eviter la destruction de cellules cerebrales
Lockey et al. Effect of oral activated charcoal on quinine elimination.
JP2007269631A (ja) 中性脂肪蓄積抑制剤
JP4974553B2 (ja) アセトアルデヒド代謝促進剤
KR100512912B1 (ko) 알코올대사 생약 촉진제
Fairweather-Tait et al. Orange juice enhances aluminium absorption from antacid preparation
WO2004035074A1 (fr) Composition servant a reduire le taux de glucose sanguin, comprenant un extrait de produit naturel
CN113559152A (zh) 护肝中药组合物、饮品及其制备方法和应用
WO2006064761A1 (fr) Agent régulateur d'adiponectine et aliments, boissons, additifs alimentaires et médicaments incluant ledit agent
KR101221623B1 (ko) 포도근 추출물을 유효성분으로 함유하는 스트레스 완화, 피로회복 또는 운동수행능력 증강용 식품조성물
JP2007008883A (ja) 血糖値低下作用を有する組成物
JPH0940568A (ja) カフェイン興奮作用抑制剤
JP2004024104A (ja) プロポリス抽出物、その製造方法、それを含有する血圧降下剤、食品製剤及びプロポリス組成物
KR0179088B1 (ko) 홍경천 추출물을 함유하는 당뇨병 예방 및 치료제 조성물
JP3492061B2 (ja) ヘリコバクター・ピロリ・アルコールデヒドロゲナーゼ阻害組成物
US20230027104A1 (en) Nutritional powder comprising oligopeptides and applications thereof
JP2006328025A (ja) 一酸化窒素調節剤、それを含有する飲食品、食品添加物、医薬及び香粧品

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase